Skip to main content

Advertisement

Log in

Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience

  • Original Article
  • Published:
Updates in Surgery Aims and scope Submit manuscript

Abstract

Peritoneal metastases from gastric cancer (PM-GC) have a detrimental prognostic impact on survival and there is a lack of consensus regarding treatment. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a chance for prolonged survival as compared to standard chemotherapy. This study aims to present our experience in the management of GC with CRS and HIPEC. This is a single-centre retrospective study. Patients were divided into two groups: patients with GC at high risk for developing PM-GC (adjuvant HIPEC group) and patients with PM-GC or positive peritoneal cytology (therapeutic CRS and HIPEC group). Overall survival (OS) and disease-free survival (DFS) were considered as outcome measures. A total of 41 patients with a GC primary received surgery and HIPEC: 14 patients (34.1%) were in the adjuvant HIPEC group, while 27 patients (65.9%) were in the therapeutic CRS and HIPEC group. In the adjuvant HIPEC group, the 1- and 3-year OS were 85.7% and 71.4%, while 1- and 3-year DFS were 71.4% and 64.3%, respectively. In the therapeutic CRS and HIPEC group, OS was 60.3% and 35.1% at 1 and 3 years, whereas 1- and 3-year DFS were 38% and 32.6%, respectively. Univariate survival analysis of patients in the therapeutic CRS and HIPEC group showed that the presence of lymph node metastasis and signet ring cell histology predicted worse OS, while PCI > 12 and lymph node metastasis were associated with decreased DFS. Treatment of highly selected patients with GC at high risk of peritoneal recurrence or established PM with CRS and HIPEC showed satisfactory results in terms of OS and DFS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Thomassen I, Bernards N, Van GYR, Jacobs EM, Lemmens VE, De HIH (2014) Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin. Acta Oncol. https://doi.org/10.3109/0284186X.2013.850740

    Article  Google Scholar 

  2. Badgwell B, Das P, Ajani J (2017) Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. https://doi.org/10.1186/s13045-017-0517-9

    Article  Google Scholar 

  3. Thomassen I, VanGestel YR, Van Ramshorst B et al (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 628:622–628. https://doi.org/10.1002/ijc.28373

    Article  CAS  Google Scholar 

  4. Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies results of the EVOCAPE 1 multicentric prospective study. Cancer 1:358–363

    Article  Google Scholar 

  5. Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF (2006) Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 243(2):189–195. https://doi.org/10.1097/01.sla.0000197382.43208.a5

    Article  Google Scholar 

  6. Yarema R, Ohorchak M, Hyrya P (2020) Gastric cancer with peritoneal metastases: efficiency of standard treatment methods. WJGO. 12(5):569–581

    Article  Google Scholar 

  7. Ikoma N, Blum M, Chiang Y et al (2016) Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. https://doi.org/10.1245/s10434-016-5409-7

    Article  Google Scholar 

  8. Ikoma N, Chen H, Wang X et al (2017) Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol 24(March):2679–2687. https://doi.org/10.1245/s10434-017-5838-y

    Article  Google Scholar 

  9. Spolverato G, Ejaz A, Kim Y et al (2014) Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg 219(4):664–675. https://doi.org/10.1016/j.jamcollsurg.2014.03.062

    Article  Google Scholar 

  10. Yonemura Y, Bandou E, Kazuo K et al (2003) Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 12(3):635–648

    Article  Google Scholar 

  11. Homma Y, Ushida S, Yamada M, Kobayashi H (2009) Positive peritoneal washing cytology in multiple cavities can predict poor prognosis of advanced gastric cancer patients. Ann Surg Oncol 2010:455–460. https://doi.org/10.1245/s10434-009-0764-2

    Article  Google Scholar 

  12. Coccolini F, Cotte E, Glehen O et al (2014) Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 40(1):12–26. https://doi.org/10.1016/j.ejso.2013.10.019

    Article  CAS  Google Scholar 

  13. Liu Y, Du Y, Chen B (2019) Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials. J Int Med Res. https://doi.org/10.1177/0300060519882545

    Article  Google Scholar 

  14. Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. EJSO 42:1123–1131. https://doi.org/10.1016/j.ejso.2016.03.016

    Article  CAS  Google Scholar 

  15. Glehen O, Gilly FN, Arvieux C et al (2010) Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377. https://doi.org/10.1245/s10434-010-1039-7

    Article  Google Scholar 

  16. Yang X, Huang C, Suo T, Mei L, Yang G (2010) cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Annu Surg Oncol 2011:1575–1581. https://doi.org/10.1245/s10434-011-1631-5

    Article  Google Scholar 

  17. Rudloff U, Langan RC, Mullinax JE, Beane JD, Seth M (2014) Impact of maximal cytoreductive surgery plus regional heated intra-peritoneal chemotherapy (HIPEC) on outcomes of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA Trial. J Surg Oncol 110(3):275–284. https://doi.org/10.1002/jso.23633.Impact

    Article  Google Scholar 

  18. Bonnot PE, Piessen G, Kepenekian V et al (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37(23):2028–2040. https://doi.org/10.1200/JCO.18.01688

    Article  CAS  Google Scholar 

  19. Fugazzola P, Coccolini F, Montori G et al (2017) Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis. J Gastrointest Oncol 8(3):572–582. https://doi.org/10.21037/jgo.2017.03.11

    Article  Google Scholar 

  20. Badgwell B, Ikoma N, Murphy MB, Wang X (2021) A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol 28(1):258–264. https://doi.org/10.1245/s10434-020-08739-5

    Article  Google Scholar 

  21. Smyth EC, Verheij M, Allum W et al (2016) clinical practice guidelines Gastric cancer: ESMO Clinical Practice Guidelines for clinical practice guidelines. ESMO Updat Clin Pract Guidel 27(August):v38–v49. https://doi.org/10.1093/annonc/mdw350

    Article  CAS  Google Scholar 

  22. Clinical N, Guidelines P, Guidelines N. Gastric Cancer. Published online 2021.

  23. Consensus C, Group W (2019) The Chicago consensus on peritoneal surface malignancies: management of gastric metastases. Annu Surg Oncol 2020:1768–1773. https://doi.org/10.1245/s10434-020-08320-0

    Article  Google Scholar 

  24. Gilly FN, Cotte E, Brigand C, Monneuse O (2006) Quantitative prognostic indices in peritoneal carcinomatosis. EJSO 32:597–601. https://doi.org/10.1016/j.ejso.2006.03.002

    Article  CAS  Google Scholar 

  25. Jacquet P, Sugarbaker P (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374

    Article  CAS  Google Scholar 

  26. Dindo D, Demartines N, Clavien P (2004) Classification of surgical complications 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae

    Article  Google Scholar 

  27. Sugarbaker PH (2007) Peritonectomy procedures. Perit Carcinomatosis A Multidiscip Approach 221(1):247–264. https://doi.org/10.1007/978-0-387-48993-3_15

    Article  Google Scholar 

  28. Bernards N, Creemers GJ, Nieuwenhuijzen GAP, Bosscha K, Pruijt JFM, Lemmens VEPP (2013) No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol 24(12):3056–3060. https://doi.org/10.1093/annonc/mdt401

    Article  CAS  Google Scholar 

  29. Yan TD, Mbbs M, Black D et al (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Annu Surg Oncol 14(10):2702–2713. https://doi.org/10.1245/s10434-007-9487-4

    Article  Google Scholar 

  30. Glehen O, Passot G, Villeneuve L et al (2014) GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 14(1):1–10. https://doi.org/10.1186/1471-2407-14-183

    Article  CAS  Google Scholar 

  31. Kang L, Mok K, Liu S et al (2013) Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion. J Chinese Med Assoc 76(8):425–431. https://doi.org/10.1016/j.jcma.2013.04.004

    Article  CAS  Google Scholar 

  32. Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B (2021) Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol 34(11):1246–1252. https://doi.org/10.1016/j.ejso.2007.12.003

    Article  Google Scholar 

  33. Rau B, Brandl A, Thuss P et al (2019) The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Gastric Cancer 22(6):1226–1237. https://doi.org/10.1007/s10120-019-00969-1

    Article  CAS  Google Scholar 

  34. Manzanedo I, Pereira F, Caro CR, Gutie A, Martı G (2019) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol 26:2615–2621. https://doi.org/10.1245/s10434-019-07450-4

    Article  Google Scholar 

  35. Koemans WJ, Van Der KRT, Boot H et al (2019) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer 19:1–8

    Article  Google Scholar 

  36. Benizri EI, Ph D, Bereder J, Rahili A, Bernard J, Benchimol D (2013) Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer. Am J Surg 205(6):668–673. https://doi.org/10.1016/j.amjsurg.2012.06.009

    Article  Google Scholar 

  37. White MG, Kothari A, Ikoma N, Murphy MB (2020) Factors associated with resection and survival after laparoscopic HIPEC for peritoneal gastric cancer metastasis. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-08842-7

    Article  Google Scholar 

  38. Stark AP, Ikoma N, Chiang YJ et al (2019) Characteristics and survival of gastric cancer patients with pathologic complete response to preoperative therapy. Ann Surg Oncol 26(11):3602–3610. https://doi.org/10.1245/s10434-019-07638-8

    Article  Google Scholar 

  39. Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B (2021) Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi- institutional cohort from PSOGI. Eur J Surg Oncol 47(1):172–180. https://doi.org/10.1016/j.ejso.2020.10.006

    Article  Google Scholar 

  40. Wang R, Song S, Harada K et al (2020) Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. https://doi.org/10.1136/gutjnl-2018-318070

    Article  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

NA and SMa: conceptualisation, data analysis, writing, review and editing; FB: conceptualisation, data collection; PF: data collection; MP, GM and FC: conceptualisation, review and editing, supervision; SM, BM, SM, LC, AL and LA: supervision. All the authors reviewed the final version of the paper and gave final approval for submission.

Corresponding author

Correspondence to Stefano Magnone.

Ethics declarations

Conflict of interest

The authors declare no competing interest.

Research involving human participants and/or animals

This study was conducted under the WMA declaration of helsinki and is compliant with Ethical Standards, Research involving human participants and/or animals.

Informed consent

Due to the retrospective nature, consent for participation in the study was waived, and no direct referral to patient data is evident.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Allievi, N., Bianco, F., Pisano, M. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience. Updates Surg 75, 159–167 (2023). https://doi.org/10.1007/s13304-022-01399-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13304-022-01399-y

Keywords

Navigation